Pharvaris (NASDAQ:PHVS) Short Interest Up 24.7% in February

Pharvaris (NASDAQ:PHVS) saw a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 487,300 shares, an increase of 24.7% from the February 13th total of 390,900 shares. Currently, 2.8% of the shares of the company are sold short. Based on an average daily trading volume, of 55,500 shares, the days-to-cover ratio is currently 8.8 days.

Institutional Trading of Pharvaris

Several hedge funds have recently bought and sold shares of PHVS. Patient Square Capital LP bought a new stake in Pharvaris in the 3rd quarter valued at about $4,488,000. Soleus Capital Management L.P. lifted its position in Pharvaris by 36.2% in the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock valued at $15,617,000 after purchasing an additional 216,483 shares during the last quarter. FMR LLC lifted its position in Pharvaris by 3.6% in the 4th quarter. FMR LLC now owns 5,395,370 shares of the company’s stock valued at $103,429,000 after purchasing an additional 189,714 shares during the last quarter. Octagon Capital Advisors LP lifted its position in Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock valued at $14,914,000 after purchasing an additional 157,530 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Pharvaris by 36.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock valued at $8,510,000 after purchasing an additional 118,408 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, JMP Securities raised their price target on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Friday, January 31st.

Pharvaris Stock Performance

Pharvaris stock opened at $15.96 on Wednesday. The firm’s 50-day moving average is $17.03 and its 200-day moving average is $19.11. Pharvaris has a 1 year low of $14.14 and a 1 year high of $26.57. The company has a market cap of $834.55 million, a P/E ratio of -5.70 and a beta of -3.02.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.